AOD-9604
Synthetic HGH fragment (amino acids 176-191) with a tyrosine addition. Promotes fat loss without the metabolic side effects of full-length GH. Does not elevate IGF-1.
Overview
Synthetic HGH fragment (amino acids 176-191) with a tyrosine addition. Promotes fat loss without the metabolic side effects of full-length GH. Does not elevate IGF-1.
Does not elevate IGF-1 or impair glucose tolerance (unlike full-length GH). Does not affect hormones, liver enzymes, or haematology. May preferentially reduce visceral/abdominal fat. Placebo-like safety profile in clinical trials.
Compound Guide
Structure: Modified 16-amino acid fragment of the C-terminus of human growth hormone (HGH 176-191) with a tyrosine residue at position 1. Retains fat-metabolising activity without GH's growth-promoting effects.
Dosage:
- Fat loss: 300-500mcg/day SubQ on empty stomach
- Standard titration: 300mcg/day (weeks 1-4) → 500mcg/day (weeks 5-12)
- Cycle: 8-12 weeks
Administration:
- SubQ injection, abdomen (near target fat)
- Morning on empty stomach or before fasted cardio
- 27-30g insulin syringe
Key Notes:
- The fat-loss fragment of GH — stimulates lipolysis and inhibits lipogenesis
- Does NOT elevate IGF-1 — avoids GH-related side effects (glucose impairment, organ growth, water retention)
- Does NOT impair glucose tolerance — safe for those concerned about insulin sensitivity
- Clinical trials showed modest but statistically significant abdominal fat reduction
- Preferentially targets abdominal/visceral fat stores
- No impact on standard blood panels — no monitoring changes needed
- GRAS (Generally Recognised As Safe) status in some jurisdictions
- Can be combined with CJC-1295/Ipamorelin for fat loss + GH benefits (AOD handles fat, GHRH/GHRP handles recovery)
- Reconstitute with bacteriostatic water, store refrigerated
Usage History
Frequently Asked Questions
Quick Reference
Category
Peptide
Half-Life
Unknown (estimated minutes; metabolic effects last hours)
Detection Time
N/A